Table 1.
Summary of cases included in the final analysis
| Final diagnosis | Source (TMA or whole sections) | Number of cases | Number positive with ALK01 | Number positive with 5A4 | Comments |
|---|---|---|---|---|---|
| ALK + ALCL |
TMA (n = 31) Whole sections (n = 3) |
31 | 31 (including 3 initially called negative on TMA then positive on whole sections) | 31 | Includes cases 3, 4, and 5 that were reclassified from ALK- ALCL after staining whole sections |
| ALK − ALCL | TMA (n = 34) | 34 | 0 | 0 | |
| Primary cutaneous ALK − ALCL | Whole sections (n = 21) | 21 | 0 | 0 | |
| PTCL, NOS | TMA (n = 19) | 19 | 0 | 0 | |
| AITL | TMA (n = 1) | 1 | 0 | 0 | |
| ENKTL | TMA (n = 7) | 7 | 0 | 0 | |
| CHL | TMA (n = 10) | 10 | 0 | 0 | |
| Total | 123 | 31 | 31 |
TMA, tissue microarray; ALK − ALCL, ALK-negative anaplastic large cell lymphoma; PTCL, peripheral T cell lymphoma, not otherwise specified; CHL, classic Hodgkin lymphoma; NK/T NHL, NK/T cell lymphoma; AITL, angioimmunoblastic T cell lymphoma